Laboratorinės technologijos - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 1,499,846 | 2,086,812 | 2,324,506 | 3,700,707 | 3,961,957 | 950,749 | 3,175,968 | 4,487,799 |
| Profit before tax | 560,660 | 933,754 | 898,174 | 1,867,941 | 2,085,141 | 99,628 | 1,653,153 | 2,565,645 |
| Net profit | 474,904 | 790,027 | 762,100 | 1,569,612 | 1,769,755 | 74,734 | 1,402,922 | 2,152,881 |
| Equity | 1,370,887 | 2,160,914 | 2,923,014 | 4,492,626 | 5,792,381 | 5,467,115 | 6,870,037 | 9,022,918 |
| Liabilities | 40,459 | 202,661 | 121,327 | 182,496 | 137,796 | 53,390 | 110,309 | 477,456 |
| Non-current assets | 594,010 | 1,004,671 | 1,162,020 | 1,103,165 | 1,015,341 | 940,597 | 1,612,640 | 1,507,306 |
| Current assets | 817,020 | 1,358,429 | 1,881,826 | 3,570,269 | 4,913,305 | 4,574,957 | 5,354,422 | 7,991,475 |
| Total assets | 1,411,030 | 2,363,100 | 3,043,846 | 4,673,434 | 5,928,646 | 5,515,554 | 6,967,062 | 9,498,781 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 189,276 | 255,235 | 225,560 |
| Social insurance contributions | - | - | - | - | - | 25,480 | 26,147 | 33,460 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +44.4% | +39.1% | +11.4% | +59.2% | +7.1% | -76.0% | +234.0% | +41.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 33.7% | 33.4% | 25.0% | 33.6% | 29.9% | 1.4% | 20.1% | 22.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 34.6% | 36.6% | 26.1% | 34.9% | 30.6% | 1.4% | 20.4% | 23.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 31.7% | 37.9% | 32.8% | 42.4% | 44.7% | 7.9% | 44.2% | 48.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 37.4% | 44.7% | 38.6% | 50.5% | 52.6% | 10.5% | 52.1% | 57.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 299,969 | 424,433 | 569,271 | 986,855 | 731,434 | 193,371 | 645,955 | 912,766 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Laboratorinės technologijos - Social security debts
The company had no debts to Sodra
Laboratorinės technologijos - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Laboratorines technologijos, UAB (code 303072399) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €4.49M, up 41.3% year on year and 372.0% over two years. Net profit reached €2.15M, while profit before tax was €2.57M, confirming a strong improvement in profitability. The company’s net profit margin rose to 48.0% in 2025, compared with 44.2% in 2024 and 7.9% in 2023. The three-year trajectory shows a clear expansion, with revenue increasing from €950.7K in 2023 to €3.18M in 2024 and €4.49M in 2025, while net profit grew from €74.7K to €1.40M and then to €2.15M. The balance sheet remained solid, with total assets of €9.50M, equity of €9.02M and liabilities of €477.5K at the end of 2025. The equity ratio was 95.0%, debt-to-equity 0.05, ROE 23.9%, ROA 22.7% and asset turnover 0.47x. Revenue per employee was €1.12M.